What is Prophase Labs Inc's earnings per share (EPS)?

Prophase Labs Inc (PRPH) reported diluted earnings per share of $-1.74 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Prophase Labs Inc Financials

PRPH

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Prophase Labs Inc (PRPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PRPH FY2025 2026-06-30

Cost cutting reduced the burn, but a revenue collapse left the business leaning on liabilities instead of internally generated cash.

FY2025’s smaller cash burn was mostly a cost-reset story, not a sales recovery: SG&A fell by $18.6M from FY2024 to FY2025 while revenue fell another $2.4M. That matters because free cash flow only improved to -$8.3M after overhead was cut, showing the operating model still did not fund itself.

Liquidity is extremely tight: the current ratio was 0.1x in FY2025 and cash was just $90K. The shift is sharp because FY2023 still had a 2.3x current ratio, so this is a recent balance-sheet deterioration rather than a long-standing feature.

The cash drain is operational, not investment-led: FY2025 capital spending was $0, and free cash flow matched operating cash flow at -$8.3M. That means the business was not consuming cash to build capacity; it was consuming cash simply to keep the enterprise running.

Financial Health Signals

Financial health score pending refresh

We are recalculating Prophase Labs Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Distress

-3.62

Prophase Labs Inc scores -3.62, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.5M) relative to total liabilities ($56.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Prophase Labs Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.57x

For every $1 of reported earnings, Prophase Labs Inc generates $0.57 in operating cash flow (-$8.3M OCF vs -$14.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-2.6x

Prophase Labs Inc earns $-2.6 in operating income for every $1 of interest expense (-$18.0M vs $6.9M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.3M

YoY-35.8%

5Y CAGR-21.4%

10Y CAGR+5.6%

Prophase Labs Inc generated $4.3M in revenue in fiscal year 2025. This represents a decrease of 35.8% from the prior year.

EBITDA

-$13.2M

YoY+59.3%

Prophase Labs Inc's EBITDA was -$13.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 59.3% from the prior year.

Net Income

-$14.7M

YoY+72.4%

Prophase Labs Inc reported -$14.7M in net income in fiscal year 2025. This represents an increase of 72.4% from the prior year.

EPS (Diluted)

$-1.74

Prophase Labs Inc earned $-1.74 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$8.3M

YoY+54.8%

Prophase Labs Inc generated -$8.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 54.8% from the prior year.

Cash & Debt

$90K

YoY-86.7%

5Y CAGR-57.9%

10Y CAGR-25.3%

Prophase Labs Inc held $90K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

46M

Prophase Labs Inc had 46M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

31.9%

YoY+34.1pp

5Y CAGR+0.1pp

10Y CAGR-1.2pp

Prophase Labs Inc's gross margin was 31.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 34.1 percentage points from the prior year.

Operating Margin

-415.4%

YoY+155.2pp

5Y CAGR-401.0pp

10Y CAGR-273.0pp

Prophase Labs Inc's operating margin was -415.4% in fiscal year 2025, reflecting core business profitability. This is up 155.2 percentage points from the prior year.

Net Margin

-339.3%

YoY+448.9pp

5Y CAGR-324.7pp

10Y CAGR-196.3pp

Prophase Labs Inc's net profit margin was -339.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 448.9 percentage points from the prior year.

Return on Equity

-420.3%

YoY+305.5pp

5Y CAGR-400.1pp

10Y CAGR-379.5pp

Prophase Labs Inc's ROE was -420.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 305.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$107K

YoY-82.0%

5Y CAGR-29.9%

10Y CAGR-10.9%

Prophase Labs Inc invested $107K in research and development in fiscal year 2025. This represents a decrease of 82.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Prophase Labs Inc invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

PRPH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$4.3M-35.8%	$6.8M-80.6%	$35.0M-71.5%	$122.6M+55.2%	$79.0M+444.6%	$14.5M
Cost of Revenue	$3.0M-57.2%	$6.9M-64.4%	$19.4M-62.6%	$52.0M+40.3%	$37.1M+274.0%	$9.9M
Gross Profit	$1.4M+1022.7%	-$150K-101.0%	$15.6M-78.0%	$70.7M+68.3%	$42.0M+811.6%	$4.6M
R&D Expenses	$107K-82.0%	$594K-57.6%	$1.4M+115.0%	$652K+25.4%	$520K-17.9%	$633K
SG&A Expenses	$19.3M-49.0%	$37.9M+13.3%	$33.4M-2.7%	$34.4M+52.9%	$22.5M+200.0%	$7.5M
Operating Income	-$18.0M+53.3%	-$38.6M-82.0%	-$21.2M-189.9%	$23.6M+140.7%	$9.8M+571.0%	-$2.1M
Interest Expense	$6.9M+107.0%	$3.4M+162.7%	$1.3M+66.9%	$764K-33.4%	$1.1M+289.2%	$295K
Income Tax	$0-100.0%	$7.2M+219.6%	-$6.0M-235.4%	$4.4M+559.2%	-$968K-8166.7%	$12K
Net Income	-$14.7M+72.4%	-$53.4M-218.0%	-$16.8M-190.9%	$18.5M+194.3%	$6.3M+395.2%	-$2.1M
EPS (Diluted)	$-1.74	$-26.68-2622.4%	$-0.98-196.1%	$1.02+155.0%	$0.40+322.2%	$-0.18

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$1.2M+49.1%	$784K-11.2%	$883K-29.2%	$1.2M-12.9%	$1.4M-4.2%	$1.5M+5.5%	$1.4M-5.9%	$1.5M
Cost of Revenue	$874K+62.8%	$537K-46.6%	$1.0M+96.1%	$513K-43.3%	$905K-45.0%	$1.6M+36.9%	$1.2M-27.6%	$1.7M
Gross Profit	$295K+19.4%	$247K+300.8%	-$123K-116.8%	$734K+39.5%	$526K+450.7%	-$150K-169.8%	$215K+238.7%	-$155K
R&D Expenses	N/A	$0-100.0%	$6K+50.0%	$4K-95.9%	$97K+61.7%	$60K-50.8%	$122K-12.9%	$140K
SG&A Expenses	$2.7M-54.4%	$6.0M+28.9%	$4.6M+0.2%	$4.6M+13.0%	$4.1M-76.0%	$17.1M+159.9%	$6.6M-5.2%	$6.9M
Operating Income	-$2.4M+57.6%	-$5.7M-20.2%	-$4.8M-22.3%	-$3.9M-6.3%	-$3.7M+78.8%	-$17.3M-166.8%	-$6.5M+10.3%	-$7.2M
Interest Expense	$651K-84.7%	$4.3M+174.9%	$1.5M+163.9%	$587K+8.9%	$539K-59.2%	$1.3M+32.9%	$993K+90.2%	$522K
Income Tax	$1.4M+320.9%	-$622K-296.2%	-$157K-120.2%	$779K	$0-100.0%	$14.6M+680.4%	-$2.5M-9.7%	-$2.3M
Net Income	-$5.2M+30.0%	-$7.4M-8.2%	-$6.8M-52.9%	-$4.5M-212.8%	$4.0M+111.5%	-$34.4M-421.6%	-$6.6M-7.1%	-$6.2M
EPS (Diluted)	$-0.42	N/A	$-0.16-45.5%	$-0.11-109.7%	$1.13	N/A	$-0.35-6.1%	$-0.33

PRPH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$59.9M-5.3%	$63.2M-31.2%	$91.9M+4.9%	$87.6M-1.8%	$89.3M+184.3%	$31.4M
Current Assets	$3.1M-89.7%	$30.6M-35.6%	$47.6M-21.8%	$60.8M-0.8%	$61.3M+286.0%	$15.9M
Cash & Equivalents	$90K-86.7%	$678K-57.9%	$1.6M-82.3%	$9.1M+8.3%	$8.4M+23.4%	$6.8M
Inventory	$70K-93.9%	$1.1M-50.1%	$2.3M-42.4%	$4.0M-13.6%	$4.6M+51.4%	$3.0M
Accounts Receivable	$1.5M-92.3%	$20.1M-44.0%	$35.8M-3.3%	$37.1M-1.7%	$37.7M+1095.2%	$3.2M
Goodwill	$4.0M-24.1%	$5.2M0.0%	$5.2M-8.4%	$5.7M0.0%	$5.7M+533.6%	$901K
Total Liabilities	$56.4M+0.9%	$55.8M+31.3%	$42.5M+77.1%	$24.0M-21.7%	$30.7M+47.1%	$20.8M
Current Liabilities	$53.1M+65.2%	$32.1M+54.1%	$20.9M+29.7%	$16.1M+3.5%	$15.5M+146.6%	$6.3M
Long-Term Debt	N/A	N/A	$2.9M	$0	N/A	N/A
Total Equity	$3.5M-52.3%	$7.4M-85.1%	$49.4M-22.4%	$63.6M+8.5%	$58.6M+455.4%	$10.6M
Retained Earnings	-$73.1M-25.2%	-$58.4M-1061.1%	-$5.0M-142.8%	$11.8M+344.9%	$2.6M+172.8%	-$3.6M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$58.5M-2.3%	$59.9M-8.9%	$65.7M+56.3%	$42.0M-16.1%	$50.1M-20.7%	$63.2M-31.2%	$91.8M-2.0%	$93.7M
Current Assets	$2.9M-9.5%	$3.1M-59.5%	$7.8M-68.4%	$24.6M-0.8%	$24.8M-19.2%	$30.6M-27.5%	$42.2M-4.3%	$44.1M
Cash & Equivalents	$31K-65.6%	$90K-77.8%	$405K+139.6%	$169K+92.0%	$88K-87.0%	$678K+35.3%	$501K-71.9%	$1.8M
Inventory	$70K0.0%	$70K-73.7%	$266K-68.0%	$830K-27.5%	$1.1M+0.2%	$1.1M-71.2%	$4.0M+2.6%	$3.9M
Accounts Receivable	$1.5M+0.5%	$1.5M-53.2%	$3.3M-83.7%	$20.1M-0.6%	$20.2M+0.7%	$20.1M-36.6%	$31.6M-3.9%	$32.9M
Goodwill	$4.0M0.0%	$4.0M0.0%	$4.0M-24.1%	$5.2M0.0%	$5.2M0.0%	$5.2M0.0%	$5.2M0.0%	$5.2M
Total Liabilities	$58.9M+4.5%	$56.4M-4.2%	$58.8M+92.3%	$30.6M-12.5%	$35.0M-37.3%	$55.8M+4.0%	$53.7M+8.2%	$49.6M
Current Liabilities	$55.7M+4.9%	$53.1M-4.0%	$55.3M+115.7%	$25.6M+6.5%	$24.1M-25.2%	$32.1M+12.0%	$28.7M+2.4%	$28.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$435K-112.4%	$3.5M-48.9%	$6.9M-40.0%	$11.4M-24.4%	$15.1M+105.6%	$7.4M-80.7%	$38.1M-13.5%	$44.1M
Retained Earnings	-$78.3M-7.1%	-$73.1M-11.3%	-$65.7M-11.6%	-$58.9M-8.2%	-$54.4M+6.8%	-$58.4M-143.0%	-$24.0M-37.8%	-$17.4M

PRPH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$8.3M+52.4%	-$17.5M-47.5%	-$11.9M-141.6%	$28.6M+309.6%	-$13.6M-425.4%	-$2.6M
Capital Expenditures	$0-100.0%	$906K-56.5%	$2.1M-46.8%	$3.9M-7.4%	$4.2M+150.5%	$1.7M
Free Cash Flow	-$8.3M+54.8%	-$18.4M-32.0%	-$14.0M-156.7%	$24.6M+238.0%	-$17.9M-317.0%	-$4.3M
Investing Cash Flow	$920K-62.0%	$2.4M+276.9%	-$1.4M+34.1%	-$2.1M+89.4%	-$19.7M-1835.6%	-$1.0M
Financing Cash Flow	$6.8M-51.8%	$14.2M+146.4%	$5.8M+122.1%	-$26.0M-174.1%	$35.1M+251.6%	$10.0M
Dividends Paid	N/A	N/A	$0-100.0%	$9.4M+105.7%	$4.5M	N/A
Share Buybacks	N/A	$0-100.0%	$588K-72.7%	$2.2M+134.7%	$917K	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$748K+39.2%	-$1.2M+64.7%	-$3.5M-1311.3%	-$247K+92.7%	-$3.4M+3.9%	-$3.5M+12.9%	-$4.0M+16.6%	-$4.8M
Capital Expenditures	N/A	$0	$0	$0	$0-100.0%	$40K+4100.0%	-$1K	$0
Free Cash Flow	N/A	-$1.2M+64.7%	-$3.5M-1311.3%	-$247K+92.7%	-$3.4M+5.0%	-$3.6M+11.9%	-$4.0M+16.6%	-$4.8M
Investing Cash Flow	$12K	$0	$0-100.0%	$67K-92.1%	$853K+2232.5%	-$40K+58.8%	-$97K-178.2%	$124K
Financing Cash Flow	$677K-26.0%	$915K-75.4%	$3.7M+1326.1%	$261K-86.5%	$1.9M-48.1%	$3.7M+30.8%	$2.9M-46.3%	$5.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$0	$0	$0

PRPH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	31.9%+34.1pp	-2.2%-46.7pp	44.5%-13.1pp	57.6%+4.5pp	53.1%+21.4pp	31.7%
Operating Margin	-415.4%+155.2pp	-570.6%-509.9pp	-60.7%-79.9pp	19.2%+6.8pp	12.4%+26.7pp	-14.3%
Net Margin	-339.3%+448.9pp	-788.2%-740.3pp	-48.0%-63.0pp	15.0%+7.1pp	7.9%+22.6pp	-14.6%
Return on Equity	-420.3%+305.5pp	-725.7%-691.8pp	-34.0%-63.0pp	29.0%+18.3pp	10.7%+30.8pp	-20.1%
Return on Assets	-24.6%+59.8pp	-84.4%-66.2pp	-18.3%-39.3pp	21.1%+14.0pp	7.0%+13.8pp	-6.8%
Current Ratio	0.06-0.9	0.95-1.3	2.28-1.5	3.78-0.2	3.95+1.4	2.52
Debt-to-Equity	16.07+8.5	7.60+7.5	0.06+0.1	0.00-0.5	0.52-1.5	1.98
FCF Margin	-192.0%+80.4pp	-272.4%-232.5pp	-39.9%-60.0pp	20.1%+42.7pp	-22.6%+6.9pp	-29.5%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	25.2%-6.3pp	31.5%+45.4pp	-13.9%-72.8pp	58.9%+22.1pp	36.8%+46.8pp	-10.0%-25.2pp	15.2%+25.5pp	-10.3%
Operating Margin	-207.5%+522.8pp	-730.4%-190.8pp	-539.5%-227.3pp	-312.3%-56.3pp	-256.0%+901.3pp	-1157.3%-699.7pp	-457.6%+23.0pp	-480.6%
Net Margin	-442.7%+500.9pp	-943.6%-169.1pp	-774.5%-415.9pp	-358.6%-635.8pp	277.2%+2577.0pp	-2299.8%-1834.6pp	-465.2%-56.1pp	-409.1%
Return on Equity	N/A	-210.9%-111.2pp	-99.7%-60.6pp	-39.1%-65.3pp	26.2%+493.5pp	-467.3%-450.0pp	-17.3%-3.3pp	-14.0%
Return on Assets	-8.8%+3.5pp	-12.4%-2.0pp	-10.4%+0.2pp	-10.6%-18.6pp	7.9%+62.3pp	-54.4%-47.2pp	-7.2%-0.6pp	-6.6%
Current Ratio	0.050.0	0.06-0.1	0.14-0.8	0.96-0.1	1.03+0.1	0.95-0.5	1.47-0.1	1.58
Debt-to-Equity	N/A	16.07+7.5	8.58+5.9	2.68+0.4	2.31-5.3	7.60+6.2	1.41+0.3	1.13
FCF Margin	N/A	-156.9%+237.9pp	-394.8%-375.0pp	-19.8%+216.5pp	-236.3%+1.9pp	-238.2%+47.1pp	-285.2%+36.7pp	-321.9%

Note: The current ratio is below 1.0 (0.06), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Precipio Inc PRPO

$42.3M

Advanced Biomed Inc. ADVB

$31.4M

Inotiv Inc NOTV

$2.8M

Ispecimen Inc. ISPC

$2.8M

bioAffinity Tech BIAF

$4.1M

Frequently Asked Questions

What is Prophase Labs Inc's annual revenue?

Prophase Labs Inc (PRPH) reported $4.3M in total revenue for fiscal year 2025. This represents a -35.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Prophase Labs Inc's revenue growing?

Prophase Labs Inc (PRPH) revenue declined by 35.8% year-over-year, from $6.8M to $4.3M in fiscal year 2025.

Is Prophase Labs Inc profitable?

No, Prophase Labs Inc (PRPH) reported a net income of -$14.7M in fiscal year 2025, with a net profit margin of -339.3%.

What is Prophase Labs Inc's EBITDA?

Prophase Labs Inc (PRPH) had EBITDA of -$13.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Prophase Labs Inc's gross margin?

Prophase Labs Inc (PRPH) had a gross margin of 31.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Prophase Labs Inc's operating margin?

Prophase Labs Inc (PRPH) had an operating margin of -415.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Prophase Labs Inc's net profit margin?

Prophase Labs Inc (PRPH) had a net profit margin of -339.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Prophase Labs Inc's return on equity (ROE)?

Prophase Labs Inc (PRPH) has a return on equity of -420.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Prophase Labs Inc's free cash flow?

Prophase Labs Inc (PRPH) generated -$8.3M in free cash flow during fiscal year 2025. This represents a 54.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Prophase Labs Inc's operating cash flow?

Prophase Labs Inc (PRPH) generated -$8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Prophase Labs Inc's total assets?

Prophase Labs Inc (PRPH) had $59.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Prophase Labs Inc's capital expenditures?

Prophase Labs Inc (PRPH) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Prophase Labs Inc spend on research and development?

Prophase Labs Inc (PRPH) invested $107K in research and development during fiscal year 2025.

How many shares does Prophase Labs Inc have outstanding?

Prophase Labs Inc (PRPH) had 46M shares outstanding as of fiscal year 2025.

What is Prophase Labs Inc's current ratio?

Prophase Labs Inc (PRPH) had a current ratio of 0.06 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Prophase Labs Inc's debt-to-equity ratio?

Prophase Labs Inc (PRPH) had a debt-to-equity ratio of 16.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Prophase Labs Inc's return on assets (ROA)?

Prophase Labs Inc (PRPH) had a return on assets of -24.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Prophase Labs Inc's cash runway?

Based on fiscal year 2025 data, Prophase Labs Inc (PRPH) had $90K in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Prophase Labs Inc's Altman Z-Score?

Prophase Labs Inc (PRPH) has an Altman Z-Score of -3.62, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Prophase Labs Inc's Piotroski F-Score?

Prophase Labs Inc (PRPH) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Prophase Labs Inc's earnings high quality?

Prophase Labs Inc (PRPH) has an earnings quality ratio of 0.57x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Prophase Labs Inc cover its interest payments?

Prophase Labs Inc (PRPH) has an interest coverage ratio of -2.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.